Recent studies have found evidence that BRCA1/2m carriers with BC have high rates of response to platinum salts in the metastatic and neoadjuvant settings; currently, most of the data were derived from BRCA1/2m carriers with TNBC. The gene discussed is BRCA1; the disease is breast cancer.